At the FSED meeting, investigators highlight SGLT2 inhibitors, finerenone, and GLP-1 or GIP agents as promising strategies to ...

Investigators studied response to standard chronic kidney disease (CKD) therapies among real-world patients with monogenic forms of glomerular disease.

SGLT2 inhibitors are linked to side effects such as genital infections, dehydration, and dizziness, which may increase the risk for falls in older adults. GLP-1 drugs often cause nausea and weight ...

SGLT2 inhibitors are one of many medicines you may take to treat type 2 diabetes. They also can protect your kidneys and make heart failure less likely. (Photo Credit: Moment RF/Getty Images) SGLT2 ...

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...